Law Firms Seek Soleno Investors Ahead of May 5 Lead‑Plaintiff Deadline

The notices spotlight claims that Soleno downplayed safety risks tied to its Prader‑Willi syndrome drug, a dispute that could shape investor recovery efforts.

Overview

In March 2026, several shareholder firms issued fresh notices urging Soleno investors who bought shares between March 26 and November 4, 2025 to consider seeking lead‑plaintiff status by May 5, 2026.
The complaint says Soleno made false or misleading statements by downplaying Phase 3 safety signals for DCCR, including reports of excess fluid retention that could affect the drug’s use and value.
Soleno’s September 10, 2025 SEC filing disclosed that a patient died after taking DCCR, and the complaint says the stock fell about 19% over the next two trading days.
Other events cited include an August 15, 2025 short‑seller report alleging trial and safety problems, and a November 4, 2025 company update that referenced launch disruption and higher discontinuations, both followed by share declines.
The class has not been certified and the allegations remain unproven, and the notices explain that investors may contact counsel on a contingency basis or remain absent class members without taking action.